Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;19(6):599-610.
doi: 10.1177/17474930241242266. Epub 2024 Apr 9.

Reducing the global burden of cerebral venous thrombosis: An international research agenda

Jonathan M Coutinho  1 , Anita van de Munckhof  1 , Diana Aguiar de Sousa  2 , Sven Poli  3   4 , Sanjith Aaron  5 , Antonio Arauz  6 , Adriana B Conforto  7 , Katarzyna Krzywicka  1 , Sini Hiltunen  8 , Erik Lindgren  9 , Mayte Sánchez van Kammen  1 , Liqi Shu  10 , Tamam Bakchoul  11 , Rosalie Belder  12 , René van den Berg  13 , Elisheva Boumans  14 , Suzanne Cannegieter  15 , Vanessa Cano-Nigenda  6 , Thalia S Field  16 , Isabel Fragata  2   17 , Mirjam R Heldner  18 , María Hernández-Pérez  19 , Frederikus A Klok  20 , Ronen R Leker  21 , Lia Lucas-Neto  22 , Jeremy Molad  23 , Thanh N Nguyen  24 , Dirk-Jan Saaltink  25 , Gustavo Saposnik  26 , Pankaj Sharma  27 , Jan Stam  1 , Vincent Thijs  28   29 , Michiel van der Vaart  30 , David J Werring  31 , Diana Wong Ramos  32 , Shadi Yaghi  10 , Nilüfer Yeşilot  33 , Turgut Tatlisumak  9 , Jukka Putaala  8 , Katarina Jood  9 , Marcel Arnold  18 , José M Ferro  34
Affiliations
Review

Reducing the global burden of cerebral venous thrombosis: An international research agenda

Jonathan M Coutinho et al. Int J Stroke. 2024 Jul.

Abstract

Background: Due to the rarity of cerebral venous thrombosis (CVT), performing high-quality scientific research in this field is challenging. Providing answers to unresolved research questions will improve prevention, diagnosis, and treatment, and ultimately translate to a better outcome of patients with CVT. We present an international research agenda, in which the most important research questions in the field of CVT are prioritized.

Aims: This research agenda has three distinct goals: (1) to provide inspiration and focus to research on CVT for the coming years, (2) to reinforce international collaboration, and (3) to facilitate the acquisition of research funding.

Summary of review: This international research agenda is the result of a research summit organized by the International Cerebral Venous Thrombosis Consortium in Amsterdam, the Netherlands, in June 2023. The summit brought together 45 participants from 15 countries including clinical researchers from various disciplines, patients who previously suffered from CVT, and delegates from industry and non-profit funding organizations. The research agenda is categorized into six pre-specified themes: (1) epidemiology and clinical features, (2) life after CVT, (3) neuroimaging and diagnosis, (4) pathophysiology, (5) medical treatment, and (6) endovascular treatment. For each theme, we present two to four research questions, followed by a brief substantiation per question. The research questions were prioritized by the participants of the summit through consensus discussion.

Conclusions: This international research agenda provides an overview of the most burning research questions on CVT. Answering these questions will advance our understanding and management of CVT, which will ultimately lead to improved outcomes for CVT patients worldwide.

Keywords: CVT; epidemiology; international; pathophysiology; summit; thrombosis; treatment.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.M.C. has received research support paid to his institution from Boehringer Ingelheim, Bayer, and Astra Zeneca. J.M.C. is co-founder and shareholder of TrianecT; D.A.d.S. reported personal fees for Astra Zeneca, Organon, Daiichi Sankyo and Johnson & Johnson advisory board participation, DSMB participation for the SECRET trial (University of British Columbia), and speaking fees from Bayer and Bial; S.P. has received research support from BMS/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, European Union, German Federal Joint Committee Innovation Fund, German Federal Ministry of Education and Research, Helena Laboratories, and Werfen as well as speakers’ honoraria/consulting fees from Alexion, Astra Zeneca, Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Portola, and Werfen; A.A. has received research support paid to his Institution from Astra Zeneca; M.S.v.K. has received research support from the Amstol foundation; R.v.d.B. has received research support paid to his institution from CERENOVUS; T.S.F. has received in-kind study medication from Bayer Canada and has received personal fees from Bayer Canada and Roche for advosiry board participation; M.R.H. has received grants from the Swiss National Science Foundation, the SITEM Research Funds, and the Swiss Heart Foundation, all outside the submitted work; M.H.-P. has received compensation for scientific research by AptaTargets; F.A.K. has received research support from Bayer, BMS, BSCI, Astra Zeneca, MSD, Leo Pharma, Actelion, Farm-X, The Netherlands Organization for Health Research and Development, The Dutch Thrombosis Foundation, The Dutch Heart Foundation, and the Horizon Europe Program; R.R.L. has received speaker honoraria from IscemaView, Boehringer Ingelheim, Pfizer, Jansen, Biogen, Medtronic, and Abott and advisory board honoraria from Jansen, Bayer, and Filterlex; T.N.N. has disclosed advisory board for Idorsia and Brainomix; G.S. has received a stipend as the Editor-in-Chief of the World Stroke Academy for the World Stroke Organization; V.T. has received speaker honoraria from Boehringer Ingelheim and Bayer & Astra Zeneca and is on the steering committee of the Librexia Stroke trial, sponsored by Johnson & Johnson; D.J.W. has received grant funding from the Stroke Association and British Heart Foundation, speaking honoraria from Bayer, speaking and chairing honoraria from Alexion and NovoNordisk, and consultancy fees from Alnylam, Bayer, and NovoNordisk; T.T. has served/serves on scientific advisory boards for Astra Zeneca, Argenx, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Inventiva, and Portola Pharm and has received academic funding from University of Gothenburg, Sahlgrenska University Hospital, European Union, Sigrid Juselius Foundation, and Wennerström’s Foundation. The other authors have nothing to disclose.

Figures

Figure 1.
Figure 1.
Structure of the meeting sessions.
See this image and copyright information in PMC

References

    1. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke 2012; 43: 3375–3377. - PubMed
    1. Zhou LW, Yu AYX, Ngo L, Hill MD, Field TS. Incidence of cerebral venous thrombosis: a population-based study, systematic review, and meta-analysis. Stroke 2023; 54: 169–177. - PubMed
    1. Coutinho JM, Ferro JM, Canhao P, et al.. Cerebral venous and sinus thrombosis in women. Stroke 2009; 40: 2356–2361. - PubMed
    1. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F. and ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35: 664–670. - PubMed
    1. Ferro JM, Bousser MG, Canhao P, et al.. European stroke organization guideline for the diagnosis and treatment of cerebral venous thrombosis—endorsed by the European Academy of Neurology. Eur J Neurol 2017; 24: 1203–1213. - PubMed

MeSH terms